Arthroscopic meniscal procedures are the most commonly performed orthopaedic procedure in the U.S. affecting 15% of Americans ages 10-65 years. Meniscus injury is also known to increase the risk of posttraumatic osteoarthritis (PTOA). The current randomized clinical trial will test a novel intervention after meniscal repair that combines an oral senolytic fisetin and real-time biofeedback program to restore joint loading and subsequent return to activity.

开始日期2025-07-01

申办/合作机构

University of Kentucky

NCT06796374

/ Not yet recruitingN/AIIT

A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1

This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers:
Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40)
The purpose of this study is:
1. To describe the fisetin kinetics after a single dose oral administration in older age.
2. To compare the fisetin kinetics after a single dose oral administration in old and young age.
FISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. 65 years and older), we want to compare fisetin kinetic parameters in two different fisetin formulations and dosages :
Arm 1) 100 mg fisetin (1x 1 capsule), cohort 1: young age Arm 2) 100 mg fisetin (1x 1 capsule), cohort 2: old age Arm 3) 1000 mg fisetin + 200 mg quercetin (2x 1 softgel capsule), cohort 1: young age Arm 4) 1000 mg fisetin + 200 mg quercetin (2x 1 softgel capsule), cohort 2: old age

开始日期2025-02-01

申办/合作机构

University of Greifswald

NCT06431932

/ Not yet recruiting临床1/2期IIT

Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.
We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.

开始日期2025-01-01

申办/合作机构

Hvidovre University Hospital

[+2]

100 项与漆黄素相关的临床结果

登录后查看更多信息

100 项与漆黄素相关的转化医学

登录后查看更多信息

100 项与漆黄素相关的专利（医药）

登录后查看更多信息

3,508

项与漆黄素相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Fisetin mitigates cisplatin-induced peripheral neuropathy: a behavioral and immunohistochemical study

Article

作者: Yilmaz, Şenay Görücü ; Çevik, Sena ; Adıgüzel, Cansel ; Yildirim, Caner ; Bal, Ramazan

BACKGROUND:

Cisplatin (CIS), a commonly used chemotherapeutic drug, often causes peripheral neuropathy, considerably affecting patients' quality of life. The present study investigated the neuroprotective effects of fisetin, a natural flavonoid with antioxidant and anti-inflammatory features, in a rat model of cisplatin-induced peripheral neuropathy.

METHODS AND RESULTS:

Male Wistar rats were divided into six groups: sham, neuropathy (CIS, 3 mg/kg, 5 weeks), fisetin treatment (CIS + 10 mg/kg and CIS + 20 mg/kg), and drugs control groups (10 mg/kg and 20 mg/kg fisetin alone). Behavioural experiments were conducted to evaluate motor coordination and sensory function, electrophysiologically measured nerve conduction velocity (NCV). Gene expression studies were conducted for NF-kB and GPX4 to investigate oxidative stress and inflammation. Finally, confocal microscopy studies were used to evaluate the structure of the sciatic nerve. Cisplatin induced motor impairments, sensory dysfunction, mechanical allodynia, diminished nerve conduction velocity, myelin deterioration (decreased MBP), and increased neuroinflammation (elevated GFAP and NF-kB, decreased GPX4). Fisetin, specifically at a dose of 10 mg/kg, markedly enhanced motor coordination, sensory thresholds, NCV, maintained myelin integrity, reduced glial activation, and restored oxidative and inflammatory balance by elevating GPX4 levels and decreasing NF-kB expression.

CONCLUSIONS:

These results highlight fisetin's potential as a therapeutic agent for cisplatin-induced neuropathy, emphasising its role in restoring molecular, structural, and functional integrity within the peripheral nervous system.

2025-08-01·MICROBIAL PATHOGENESIS

Effects of fisetin on virulence of Actinobacillus Pleuropneumoniae

Article

作者: He, Qiyun ; Ye, Chunyan ; Chen, Huanchun ; Qi, Song ; Chen, Yunpeng ; Bei, Weicheng ; Zheng, Yaxuan ; Yan, Kang

Porcine infectious pleuropneumonia (PCP), caused by Actinobacillus pleuropneumoniae (APP), is a highly infectious respiratory disease of pigs, resulting in significant economic losses to the industry. Apx toxins are cytolytic virulence factors produced by APP. The natural flavonoid fisetin has a variety of biological activities, including antioxidant and anti-inflammatory properties. This study aimed to investigate the protective effects of fisetin against APP. Fisetin was found to effectively inhibit the hemolytic activity of both APP culture supernatants and the purified toxins, and blood agar plate results also showed that the addition of fisetin to APP reduced the diameter of the hemolytic zone. Fisetin did not influence the expression of Apx toxins, although it reduced that of the virulence factor CPS. In vitro, fisetin effectively inhibited APP cytotoxicity and intracellular colonization, as well as intracellular ROS production. Furthermore, it reduced the expression of IL-6, TNF-α, and TLR4 in porcine alveolar macrophages (3D4/21). In vivo, fisetin reduced APP colonization of mouse lung tissues and improved the survival rate of APP-infected mice. In conclusion, fisetin was found to reduce the release of pro-inflammatory cytokines and ROS, decrease the risk of hemolysis, and attenuate APP virulence. The findings highlight the potential therapeutic value of fisetin in the management of APP infection. Further investigations into the mechanisms underlying the effects of fisetin are warranted.

2025-08-01·FOOD CHEMISTRY

Copper(II)-Bathocuproine reagent−based dual mode sensing of total antioxidant capacity in food extracts

Article

作者: Apak, Reşat ; Şen, Furkan Burak ; Bener, Mustafa ; Yermeydan Peker, Müge

As food antioxidants are known deactivators of reactive species that may cause oxidative hazard, antioxidant capacity determination has gained importance in biochemistry, medicine and food science. In this study, a simple and sensitive dual-mode system based on spectrophotometric (SP) and spectrofluorometric (SF) determination of food antioxidants was developed using the Cu(II) complex of fluorescent bathocuproine sulfonate disodium salt (BCDS). In the proposed SF assay of total antioxidant capacity (TAC), a linear decrease in fluorescence occurs related to the formation of non-fluorescent Cu(I)-BCDS chelate depending on antioxidant concentration. At the same time in the SP method, the chemical reduction of Cu(II)-BCDS complex by antioxidants reflected in the absorbance increase of the formed Cu(I)-BCDS complex is monitored. By optimizing the optimal experimental conditions of the developed methods and applying them to standard antioxidant compounds separately, calibration equations were obtained and Trolox Equivalent Antioxidant Capacity (TEAC) values were calculated. The LOD values for Trolox obtained by SP and SF methods were found to be 0.16 and 5.08 μmolL^-1, respectively. The sensitivity and accuracy of these two systems were examined by spiking known amounts of antioxidants to complex sample matrices. Both methods were successfully applied to the determination of TAC in food extracts. This dual sensing system is novel in view of the fact that the same probe (Cu(II)-BCDS) is used in the simple, rapid and sensitive determination of the same analyte (TAC) in two different (SP and SF) modes.

项与漆黄素相关的新闻（医药）

2025-04-14

·Business Wire

BeFisetin® Announced the Global No.1 All-Natural Fisetin With SA-GRAS Status

NEW YORK--(BUSINESS WIRE)--Bonerge Lifescience, a trusted innovator in longevity ingredients, proudly announces a historic milestone: on April 2, 2025, its premium fisetin ingredient, BeFisetin®, has achieved Self-affirmed Generally Recognized as Safe (SA-GRAS) status in the United States. This landmark accomplishment positions Bonerge as the first company globally to secure GRAS certification for fisetin powder, setting a new global benchmark for safety and reliability in the next-generation anti-aging market. BeFisetin: Establishing the Gold Standard to Address Chaos in the Fisetin Market The current fisetin market is plagued by alarming quality inconsistencies. While vague claims of "Fisetin 98% HPLC" dominate as the mainstream specification, actual fisetin content in these products ranges only between 75%-85%, with significant impurities concealed under this ambiguous standard. For plant extracts derived from non-edible sources, the removal of harmful components is critical. Fisetin, extracted from inedible Anacardiaceae plants, contains large amounts of toxic lacquer, waxes, and wood debris. Eliminating these impurities is essential to producing safe, high-quality fisetin. Yet, the absence of clear, stringent quality standards has made it impossible to verify purity, allowing low-quality products to flood the market. Many suppliers exploit rudimentary testing methods to falsely label products as "98% HPLC," misleading consumers and perpetuating a cycle where inferior products overshadow genuine quality. This chaos forces brands to settle for subpar fisetin, stifling innovation in premium formulations. Establishing a gold standard for fisetin quality has been Bonerge’s mission from the start. Recognizing the challenges—extensive R&D, industry-first breakthroughs, and short-term financial sacrifices—we named our product BeFisetin as a constant reminder: "To be or not to be" hinges on our commitment to redefine excellence in fisetin. BeFisetin is not just a product—it’s a pledge to restore integrity and drive progress in the fisetin industry. What Defines the Gold Standard for Fisetin? Safety First : SA-GRAS certification ensures systemic safety evaluation, a critical gateway for market entry. Transparent Quality Metrics : BeFisetin guarantees 98% HPLC purity , 98% HPLC content , 99% total active ingredients , and <1% impurities , setting unmatched benchmarks for consistency and quality. Ongoing Clinical Validation : Bonerge has completed the first double-blind, controlled clinical trial on BeFisetin’s efficacy in skin health, with results under analysis and pending publication. A second large-scale trial on sleep and immune health, approved by ethics committees in March, is now underway. BeFisetin: The 1st All-Natural Fisetin to be Granted SA-GRAS BeFisetin® is the first all-natural fisetin to attain SA-GRAS certification. For all dietary supplement ingredients, SA-GRAS represents a critical milestone, but its significance is unparalleled in advancing fisetin as a premium raw material. This certification sets the gold standard for the industry, requiring adherence to rigorous criteria: well-defined quality specifications, scientifically validated testing protocols, GMP-compliant manufacturing environments, and comprehensive safety assessments—all of which elevate fisetin from an underregulated botanical to a clinically trusted ingredient. By establishing these benchmarks, SA-GRAS not only ensures consumer safety but also paves the way for innovation in longevity-focused formulations. “Beyond regulatory compliance, this accomplishment reflects our foundational commitment to scientific excellence and consumer safety—principles that drive every stage of our ingredient innovation,” stated Gloria, Product Manager of Bonerge. “SA-GRAS BeFisetin® provides brands with a scientifically validated ingredient that meets international regulatory requirements, enabling them to develop innovative products with assurance.” A Vision for Trusted Longevity Foundation The GRAS certification of BeFisetin® marks the beginning of Bonerge’s mission to redefine aging. By prioritizing rigorous science and consumer safety, Bonerge aims to foster transparency in the anti-aging market, and we are committed to providing scientifically grounded solutions that empower individuals to age healthily. As global interest in senotherapeutics grows, BeFisetin® stands at the forefront, offering brands a trusted, scalable ingredient to meet the rising demand for effective and safe longevity products.

上市批准

2025-01-09

·Business Wire

Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

NEW YORK--( BUSINESS WIRE )--Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market. Senolytics Research: Advancing the Science of Anti-Aging In recent years, Senolytics research has advanced rapidly, with institutions like the Mayo Clinic and Wake Forest University at the forefront. Despite fruitful research, identifying optimal applications to translate Senolytics into market solutions remains crucial. In October 2024, the Mayo Clinic published groundbreaking findings in Nature Aging, identifying 67 plasma proteins, with IL-23R emerging as a promising anti-aging biomarker 1 . The study explored various promising Senolytics, including Fisetin, demonstrating a positive response in reducing senescence-related proteins and indicating potential for organ rejuvenation via senescent cell clearance 2 . The concept of organ rejuvenation offering deeper insights into its systemic effects and guiding anti-aging strategies. Senolytics show strong potential for organ rejuvenation applications and promise broader future prospects. Bonerge’s Clinical Trial: Exploring Skin as the Key to Rejuvenation The skin, the largest organ of the human body, is the most visible indicator of aging and a key target for anti-aging. Bonerge has launched a clinical trial focused on skin anti-aging, involving 108 participants. The trial evaluates skin anti-aging effects by assessing factors like skin heme, skin inflammation, transepidermal water loss, wrinkles, skin elasticity, skin firmness, melanin levels, and skin tone. Spanning 56 days, it aligns with two skin regeneration cycles, providing a detailed analysis of these key skin health indicators. Three ingredients tested in the trail: Fisetin: Among natural ingredients, fisetin has the strongest activity in clearing senescent cells. Its core mechanism promotes apoptosis of senescent cells and reduces SASP (Senescence-Associated Secretory Phenotype) secretion, alleviating chronic inflammation and combating inflammaging 3 , contributing to organ rejuvenation. Urolithin A: A rising star in nutritional supplements, Urolithin A has shown significant anti-photoaging effects. Photoaging, primarily caused by UVA (ultraviolet A) radiation, accelerates skin aging. Urolithin A helps protect skin by reducing the senescent phenotype of skin fibroblasts triggered by UVA, lowering intracellular ROS (reactive oxygen species), and activating antioxidant enzymes. These actions collectively support skin health and combat the harmful effects of photoaging 4 . Ergothioneine : Currently recognized as the only antioxidant that targets mitochondria, it reduces oxidative damage within mitochondria, supporting energy production and potentially preventing cellular aging 5 . Key Focus: Exploring Individual Ingredients and Combined Synergies In this clinical trial, while examining the skin anti-aging effects of individual ingredients, the combination of the three ingredients have also been tested to explore the synergistic effects on skin health and anti-aging. Path Ahead: Trial Progress and Future Expectations The clinical trial is progressing as planned and is expected to conclude in March 2025. Bonerge is hopeful that this study will provide valuable evidence for the anti-aging market, paving the way for the application of Senolytics in skin health and broader anti-aging treatments. References [1] Chase M. Carver, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature Aging, Dec 2024. [2] Researchers discover an aging and inflammation biomarker - Mayo Clinic News Network [3] Matthew J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36 (2018). [4] Wenjie Liu , et al. Urolithin A protects human dermal fibroblasts from UVA-induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B. 2022 Jul. [5] Brown, Lisa, et al. L-Ergothioneine and Its Protective Role in Cellular Health. Journal of Clinical Nutrition, vol 56.

临床研究

2024-12-31

·Business Wire

BeFisetin® is Gaining the First Fisetin Ingredient SA-GRAS Certification

NEW YORK--( BUSINESS WIRE )--In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market. Fisetin: The Anti-aging Potential of Natural Polyphenols Fisetin is a natural polyphenol widely present in various fruits and vegetables such as strawberries, apples, and persimmons. In recent years, the scientific community's enthusiasm for exploring fisetin has been continuously rising. Numerous research findings have revealed that fisetin has unique biological properties in reducing inflammatory factors, strengthening cell health, and delaying aging [1-3], and its related applications have also attracted extensive and in-depth attention. Biochemical studies have shown that fisetin can exert its effects through multiple mechanisms. It can effectively reduce senescent cells in the brain, skin, and various organs, regulate inflammatory factors, and scavenge free radicals [4]. This makes fisetin an attractive dietary supplement, showing broad application prospects in healthy aging and long-term health management. BeFisetin®: Marketing Strategy and Innovation As a company dedicated to the development and research of high-quality ingredients, Bonerge recognizes the growing global demand for safe and effective dietary supplements. It is Bonerge’s principle to leverage cutting-edge science to transform advanced research into practical health solutions. Bonerge is continuously improving the purity and bioavailability of BeFisetin®, while integrating sustainable production practice, demonstrating a strong commitment to environmental responsibility. Focusing on the great potential of fisetin, Bonerge has engaged in in-depth strategic collaborations with multiple research institutions and universities to strengthen the scientific validation and credibility of BeFisetin®, continuously enhancing its trust and reputation through rigorous scientific verification. This ensures consumers have access to transparent, reliable health solutions. SA-GRAS Certification: An Extended Standard in Safety and Trust SA-GRAS certification, a critical extension of the FDA's GRAS framework, allows companies to confirm the safety of their products through rigorous self-assessment. This process involves establishing stringent product standards, conducting comprehensive toxicity and safety evaluations, and systematically assessing raw materials, manufacturing processes, and product stability. Companies need to work with independent professional organizations to prepare detailed safety assessment reports, which are reviewed by an expert panel. The rigorous certification process drives Bonerge to further optimize its product quality systems and elevated BeFisetin®'s competitiveness in the global market. For Bonerge, SA-GRAS certification is not merely a regulatory milestone but a testament to its relentless pursuit of product excellence and its commitment to consumer safety. Looking Ahead: Responsibility and Opportunity The expansion of aging population is a global challenge, driving increasing demand for health-focused anti-aging solutions. Bonerge is committed to leveraging BeFisetin®'s superior quality to advance scientific research, foster innovation, and provide consumers with safer and trustworthy products. To be or not to be, that is the question! BeFisetin®: A scientific breakthrough as the world’s first SA-GRAS-certified fisetin ingredient, setting a new industry standard. References [1] Yoon S, Lee H, Kim J, et al. A natural flavonoid, fisetin, alleviates neuroinflammation and memory impairment in D-galactose-treated mice[J]. Frontiers in Pharmacology, 2023, 14: 1134733. [2] Li X, Zhang H, Guo Y, et al. Fisetin promotes osteoblastogenesis and inhibits adipogenesis in bone marrow stromal cells through the activation of the Wnt/β-catenin pathway[J]. International Journal of Molecular Sciences, 2019, 20(23): 5957. [3] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan[J]. EBioMedicine, 2018, 36: 18-28. [4] Takaya K, Kawaguchi M, Mizutani K, et al. Fisetin, a potential skin rejuvenation drug that eliminates senescent cells in the dermis[J]. Biogerontology, 2023, 24(5): 409-421.

100 项与漆黄素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB07795

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
普通可变性免疫缺陷	临床2期	美国	Mayo Clinic	2023-04-12
系统性硬化相关的间质性肺病	临床2期	美国	Mayo Clinic	2023-04-12
腕管综合征	临床2期	美国	Mayo Clinic	2022-10-09
新冠肺炎后遗症	临床2期	美国	Mayo Clinic	2020-08-03
Crouzon综合征伴黑棘皮症	临床2期	美国	Mayo Clinic	2018-02-06
炎症	临床2期	美国	Mayo Clinic	2018-02-06
肾纤维化	临床前	中国	四川大学华西医院（四川省国际医院）	2023-03-01
黑色素瘤	临床前	美国	University of Wisconsin Madison	2013-04-15
前列腺癌	临床前	美国	University of Wisconsin Madison	2009-05-01
结肠癌	临床前	美国	University of Wisconsin Madison	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	胰腺导管腺癌 CD44 \| CD24 \| CD133 ... 更多	-	Fisetin	餘膚餘醖鹽餘顧糧蓋夢(壓醖網獵淵願網窪觸膚) = 顧鹹觸糧選齋糧網獵願築壓艱鏇鹹鏇壓選製膚 (壓鏇壓淵製製廠範遞遞 )	-	2025-04-27
				Fisetin (Untreated)	餘膚餘醖鹽餘顧糧蓋夢(壓醖網獵淵願網窪觸膚) = 窪積鏇壓觸範製選膚窪築壓艱鏇鹹鏇壓選製膚 (壓鏇壓淵製製廠範遞遞 )
NCT04210986 (CTgov)	临床1/2期	膝关节炎	75	Fisetin (Fisetin)	襯積夢膚廠築衊窪壓遞 = 壓積齋糧夢願製壓觸積簾廠願製鹹鬱網憲顧壓 (簾鹽選糧夢製艱遞淵繭, 憲積鏇築醖範獵網鏇餘 ~ 獵獵憲簾廠襯選膚觸鹽) 更多	-	2024-09-19
				Placebo oral capsule (Placebo)	襯積夢膚廠築衊窪壓遞 = 醖選繭選鏇衊範範製鹽簾廠願製鹹鬱網憲顧壓 (簾鹽選糧夢製艱遞淵繭, 繭鑰齋選築簾襯構膚繭 ~ 鹽觸憲夢鬱願鹹蓋築積) 更多
NCT04771611 (COVFIS-HOME, CTgov)	临床2期	新型冠状病毒感染	55	Fisetin (Treatment Group)	夢願簾壓遞顧鹹壓顧鹹 = 鹹蓋鑰鑰憲範觸鑰淵願範壓蓋憲願築壓鬱鹽顧 (網齋襯積簾衊蓋遞網製, 獵鹹齋餘醖窪範選夢齋 ~ 衊繭製襯齋鬱觸鬱鹹醖) 更多	-	2023-08-01
				Placebo (Placebo)	夢願簾壓遞顧鹹壓顧鹹 = 膚網艱繭願淵觸鬱觸膚範壓蓋憲願築壓鬱鹽顧 (網齋襯積簾衊蓋遞網製, 積簾願觸艱選獵選鹽鹽 ~ 遞齋鹹構製衊網艱艱鑰) 更多